| exenatide
LAR |
AstraZeneca |
slow drug releasing subcutaneous
depot with 1 entrapped noncovalently into a biodegradable
PLGA microsphere |
(26) |
| microsphere |
Na et al. |
polysaccharide-based microsphere
formulation of 1
|
(130) |
| hydrogel |
Ding et al. |
triblock copolymer PLGA-PEG-PLGA-based
hydrogel formulation of 1
|
(131) |
| hydrogel |
Joabsson et al. |
lipid-based hydrogel preparation
of GLP-1 and 1 for subcutaneous injection |
(132) |
| protease-operated depot
(POD) |
Chilkoti et
al. |
thermoresponsive
depot forming
elastin-like polymers containing protease-cleavable oligomers of [Gly8]-GLP-1(7–36) with a dipeptide (Gly-Ala) added at the N-terminus |
(133) |
| implantable device |
Kuzma et al. |
polymeric hydrogel-based
implantable devices containing 1
|
(134) |
| formulation
for pulmonary
delivery |
Youn et
al. |
albumin-coated
porous hollow
PLGA microparticles bound with palmitylated exendin-4 |
(135) |
| chewing gum tablet |
Andersen et al. |
chewing gum containing GLP-1
and exendin-4 |
(136) |
| formulation for gene therapy |
Kim et al. |
exenatide plasmid in an
arginine-grafted bioreducible polymer (ABP) poly-cystaminebisacrylamidediaminohexane
as the gene carrier |
(137) |
